The Long Pentraxin PTX3 as a New Biomarker and Pharmacological Target in Age-Related Macular Degeneration and Diabetic Retinopathy.
The Long Pentraxin PTX3 as a New Biomarker and Pharmacological Target in Age-Related Macular Degeneration and Diabetic Retinopathy.
复制标题
DOI：
10.3389/fphar.2021.811344
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Inforzato A
中科院分区：
文献类型：
--
作者：
Stravalaci M;Ferrara M;Pathak V;Davi F;Bottazzi B;Mantovani A;Medina RJ;Romano MR;Inforzato A
年龄相关性黄斑变性（AMD）和糖尿病视网膜病变（DR）是眼睛的多因素、神经变性和炎性疾病，主要分别涉及外部和内部血视网膜屏障（BRB）的细胞和分子组分。AMD是一种视网膜免疫失调的典型疾病，主要由遗传因素，特别是补体基因多态性引起。DR是糖尿病的主要并发症，通常表现为血管通透性增加和视网膜血管阻塞，其以疾病的增殖形式导致新血管形成，这是与晚期AMD共有的致病特征。尽管有不同的病因学和临床表现，但这两种病理学具有共同的驱动因素，例如免疫（AMD）或代谢（DR）来源的慢性炎症，其引发并传播神经视网膜的变性，但潜在的机制仍不清楚。作为一种具有补体调节功能的可溶性模式识别分子和血管损伤的标志物，长正五聚蛋白3（PTX 3）正在成为眼内稳态的新参与者和视网膜神经退行性疾病的潜在药理学靶点。在生理上存在于人眼中并在炎症条件下诱导，这种蛋白质战略性地定位在BRB界面，在那里它充当补体的“分子陷阱”，并在稳态和病理条件下调节炎症。在这里，我们讨论了目前对PTX 3和视网膜疾病的观点，重点是AMD和DR，其中提出的五聚蛋白的作用，以及它们对开发新的治疗策略的影响。
Age related macular degeneration (AMD) and diabetic retinopathy (DR) are multifactorial, neurodegenerative and inflammatory diseases of the eye primarily involving cellular and molecular components of the outer and inner blood-retina barriers (BRB), respectively. Largely contributed by genetic factors, particularly polymorphisms in complement genes, AMD is a paradigm of retinal immune dysregulation. DR, a major complication of diabetes mellitus, typically presents with increased vascular permeability and occlusion of the retinal vasculature that leads, in the proliferative form of the disease, to neovascularization, a pathogenic trait shared with advanced AMD. In spite of distinct etiology and clinical manifestations, both pathologies share common drivers, such as chronic inflammation, either of immune (in AMD) or metabolic (in DR) origin, which initiates and propagates degeneration of the neural retina, yet the underlying mechanisms are still unclear. As a soluble pattern recognition molecule with complement regulatory functions and a marker of vascular damage, long pentraxin 3 (PTX3) is emerging as a novel player in ocular homeostasis and a potential pharmacological target in neurodegenerative disorders of the retina. Physiologically present in the human eye and induced in inflammatory conditions, this protein is strategically positioned at the BRB interface, where it acts as a “molecular trap” for complement, and modulates inflammation both in homeostatic and pathological conditions. Here, we discuss current viewpoints on PTX3 and retinal diseases, with a focus on AMD and DR, the roles therein proposed for this pentraxin, and their implications for the development of new therapeutic strategies.
登录
查看更多内容
影响因子：
9
作者：
Clark SJ;Bishop PN
通讯作者：
Bishop PN
影响因子：
4.6
作者：
Armento, Angela;Honisch, Sabina;Ueffing, Marius
通讯作者：
Ueffing, Marius
DOI：
10.4049/jimmunol.1401613
发表时间：
2014-11-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Clark SJ;Schmidt CQ;White AM;Hakobyan S;Morgan BP;Bishop PN
通讯作者：
Bishop PN
影响因子：
25.7
作者：
Bottazzi B;Inforzato A;Messa M;Barbagallo M;Magrini E;Garlanda C;Mantovani A
通讯作者：
Mantovani A
影响因子：
13.7
作者：
Acar, Ilhan E.;Lores-Motta, Laura;den Hollander, Anneke, I
通讯作者：
den Hollander, Anneke, I